Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Live Nasdaq Composite: Markets Tread Cautiously Amid Trade Deal Angst (24/7 Wall St.) +++ CORE SCIENTIFIC Aktie +7,20%

IOVANCE Aktie

 >IOVANCE Aktienkurs 
1.4806 EUR    -0.1%    (Tradegate)
Ask: 1.484 EUR / 10110 Stück
Bid: 1.4502 EUR / 1380 Stück
Tagesumsatz: 7349 Stück
Realtime Kurs von 8 bis 22 Uhr!
IOVANCE Aktie über LYNX handeln
>IOVANCE Performance
1 Woche: +2,3%
1 Monat: -7,1%
3 Monate: -45,5%
6 Monate: -79,7%
1 Jahr: -78,1%
laufendes Jahr: -78,2%
>IOVANCE Aktie
Name:  IOVANCE BIOTHERAPEUTICS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US4622601007 / A2DT49
Symbol/ Ticker:  2LB (Frankfurt) / IOVA (NASDAQ)
Kürzel:  FRA:2LB, ETR:2LB, 2LB:GR, NASDAQ:IOVA
Index:  -
Webseite:  https://www.iovance.com/
Marktkapitalisierung:  644.89 Mio. EUR
Umsatz:  184.14 Mio. EUR
EBITDA:  -316.03 Mio. EUR
Gewinn je Aktie:  -0.909 EUR
Schulden:  46.51 Mio. EUR
Liquide Mittel:  311.43 Mio. EUR
Umsatz-/ Gewinnwachstum:  6% / -
KGV/ KGV lG:  - / -
KUV/ KBV/ PEG:  3.2 / 0.97 / -
Gewinnm./ Eigenkapitalr.:  -176.49% / -51.85%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  IOVANCE
Letzte Datenerhebung:  07.07.25
>IOVANCE Eigentümer
Aktien: 333.93 Mio. St.
f.h. Aktien: 280.35 Mio. St.
Insider Eigner: 0.48%
Instit. Eigner: 81.27%
>IOVANCE Peer Group

 
07.07.25 - 18:03
 Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit (PR Newswire)
 
LOS ANGELES, July 7, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) have opportunity to lead the securities fraud class action lawsuit. IF YOU ARE AN INVESTOR......
07.07.25 - 16:06
 IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm (PR Newswire)
 
LOS ANGELES, July 7, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ: IOVA) for violations of §§10(b) and 20(a) of the Securities......
07.07.25 - 16:06
 IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV (PR Newswire)
 
LOS ANGELES, July 7, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ: IOVA) for violations of the federal securities laws. Shareholders who purchased the Company's securities......
07.07.25 - 15:02
 IOVA LAWSUIT ALERT: The Gross Law Firm Notifies Iovance Biotherapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline (PR Newswire)
 
NEW YORK, July 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). Shareholders who purchased shares of IOVA during the class period listed are encouraged to contact the firm regarding possible lead......
03.07.25 - 13:36
 SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Iovance To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Iovance between August 8, 2024 and May 8, 2025 and would like to discuss......
02.07.25 - 15:27
 IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV (PR Newswire)
 
LOS ANGELES, July 2, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ: IOVA) for violations of the federal securities laws. Shareholders who purchased the Company's securities......
02.07.25 - 15:24
 IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm (PR Newswire)
 
LOS ANGELES, July 2, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ: IOVA) for violations of §§10(b) and 20(a) of the Securities......
28.06.25 - 01:24
 Why Iovance Biotherapeutics Stock Dove by Almost 15% This Week (Fool)
 
Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...
27.06.25 - 16:01
 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA (PR Newswire)
 
NEW YORK, June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......
27.06.25 - 15:01
 Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit - IOVA (PR Newswire)
 
NEW YORK, June 27, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Iovance investors who were......
27.06.25 - 01:12
 Faruqi & Faruqi Reminds Iovance Biotherapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 14, 2025 - IOVA (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Iovance To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Iovance between August 8, 2024 and May 8, 2025 and......
26.06.25 - 23:01
 Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit (PR Newswire)
 
LOS ANGELES, June 26, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA). IF YOU SUFFERED A LOSS ON YOUR......
26.06.25 - 15:01
 The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit - IOVA (PR Newswire)
 
NEW YORK, June 26, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). Shareholders who purchased shares of IOVA during the class period listed are encouraged to contact the firm regarding possible lead......
25.06.25 - 20:18
 IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit (PR Newswire)
 
NEW YORK, June 25, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025, both dates inclusive (the "Class Period"), of the important July 14, 2025 lead......
23.06.25 - 22:09
 Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire EN)
 
SAN CARLOS, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on June 20, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 312,660 shares of Iovance's common stock to 58 new, non-executive employees....
23.06.25 - 15:01
 Iovance Biotherapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - IOVA (PR Newswire)
 
NEW YORK, June 23, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). Shareholders who purchased shares of IOVA during the class period listed are encouraged to contact the firm regarding possible lead......
20.06.25 - 21:42
 Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit (PR Newswire)
 
LOS ANGELES, June 20, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) have opportunity to lead the securities fraud class action lawsuit. IF YOU ARE AN INVESTOR......
20.06.25 - 17:48
 Faruqi & Faruqi Reminds Iovance Biotherapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 14, 2025 - IOVA (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Iovance To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Iovance between August 8, 2024 and May 8, 2025 and......
20.06.25 - 15:03
 Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit - IOVA (PR Newswire)
 
NEW YORK, June 20, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Iovance investors who were......
20.06.25 - 00:01
 IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit (PR Newswire)
 
NEW YORK, June 19, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025, both dates inclusive (the "Class Period"), of the important July 14, 2025 lead......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Es geht nichts über ein ruhiges Leben, wie der Mann sagte, als er die Stelle eines Leuchtturmwärters annahm. - Charles Dickens
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!